On November 19, Caris Life Sciences, Inc. rose 5.7% in Regular Trading, trading at $20.06 per share, with turnover of $4.7753 million.
The move aligns with a rebound pattern following recent post-earnings selling pressure, as trading volatility has continued after the company delivered third-quarter results above expectations and raised full-year revenue guidance.
Caris Life Sciences, Inc. reported quarterly EPS of $0.05, above expectations of about $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million forecast. The company also lifted full-year revenue guidance to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion previously. Even so, EPS remained below $0.08 a year earlier, indicating that investor views on valuation and growth durability remain divided despite the latest rebound.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments